We offer over 150 bulk actives manufactured at USFDAUK MHRA approved sites We

We offer over 150 bulk actives manufactured at

This preview shows page 9 - 12 out of 24 pages.

routes. We offer over 150 bulk actives manufactured at USFDA/UK MHRA approved sites. We seek out-licensing opportunities for our speciality generics, super generics, and bulk drugs for global markets. MANUFACTURING With worldclass technology and a team of strong professionals, we have built sites and systems that meet the most stringent international manufacturing standards. Expert quality teams ensure that systems and processes remain in compliance with the latest standards. A number of our plants hold approvals from the USFDA and the UK MHRA. APIs and Dosage forms are made in 19 sites across India, US, Hungary and Bangladesh. Formulation We make speciality formulations across a range of dosage forms- oral, injectable and delivery system based. API We make speciality APIs including peptides, steroids, hormones and anticancers at internationally approved worldclass sites. Quality Policy 9 | P a g e
Image of page 9
Regularly updated systems, procedures and an expert team support a stringent quality policy. Environmental Policy At Sun Pharma, a concern for safety and the environment is part of our plans. GROUP COMPANIES Caraco Pharmaceutical Laboratories Based in Detroit, Michigan, Caraco develops, manufactures, market and distributes generic and private label pharmaceuticals* and markets them throughout the United States. The corporation's present portfolio consists of a number of products in various strengths and package sizes, across a variety of therapeutic segments, including epilepsy and hypertension. For the most recent year ending March 2008, Caraco had sales of over $350 mill. Caraco's manufacturing facility and executive offices were constructed in 1991, after a $9.1 million loan from the Economic Development Corporation of the city of Detroit. Since August 1997, capital infusions and loans have primarily come from Sun Pharma. Sun Pharma's investment in and support of Caraco has resulted in, since the second quarter of 2002, Caraco achieving the sales to support its operations. As on March 2008, Sun Pharma owns approx 76% on a diluted basis of the outstanding common shares of Caraco. Sun Pharma has two R&D centers in Baroda and Mumbai, where development work for generics is done. Sun Pharmaceutical Industries Inc. (SPI) Sun Pharmaceutical Industries Inc is a Michigan Corporation and a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd, India. In the second half of 2004, Sun Pharma acquired the trademarks, manufacturing know-how and other intellectual property of certain pharmaceutical products from Women's First Healthcare, Inc, which was under bankruptcy proceedings. On completion of the acquisition in December 2004, these products were assigned to Sun Pharma Inc. In December 2005, Sun Pharma Inc completed the purchase of dosage form manufacturing operations of Able Labs in the US for USD 23.15 million from the US Bankruptcy Court of the 10 | P a g e
Image of page 10
District of New Jersey, Trenton. A plant spread over 35,000 sq ft, in Bryan, Ohio, manufactures liquids, creams, and ointments. This plant was purchased from Valeant Pharma.
Image of page 11
Image of page 12

You've reached the end of your free preview.

Want to read all 24 pages?

  • Winter '14
  • Sun Pharma, Sun Pharmaceutical Industries Ltd

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture